R&D JP Morgan 2024 – Graham Heap Just over a year ago, Takeda acquired a promising immunotherapy candidate, TAK-279, from Boston-based Nimbus Therapeutics.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
